Aurinia Pharmaceuticals Inc Conference Call to Discuss LUPKYNIS Approval Transcript
Hello, and welcome to the Aurinia Pharmaceuticals LUPKYNIS update call. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Dr. Glenn Schulman, Head of IR. Please go ahead, sir.
Thank you, Kevin, and good morning, everyone. Pleased to welcome you to today's call to discuss the FDA approval of voclosporin, now with the brand name LUPKYNIS, the first oral medicine approved by the FDA for the treatment of active lupus nephritis. Joining me on the call this morning from the Aurinia team are Mr. Peter Greenleaf, our President and CEO; Dr. Neil Solomons, Chief Medical Officer; Mr. Max Colao, our Chief Commercial Officer; and Mr. Joe Miller, Chief Financial Officer.
On the evening of Friday, January 22, we issued a press release announcing the approval of LUPKYNIS, which is accessible from our website at www.auriniapharma.com
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |